Anonymous
Guest
Anonymous
Guest
...senior management remains upbeat on growth prospects for Xtandi. In fact, chief executive officer David Hung boasted to analysts on the second-quarter earnings call that Xtandi is “quickly becoming the leading therapy in the post-docetaxel market.” Unfortunately, this promulgation lacks veracity - See more at: http://ycharts.com/analysis/story/a...00_times_future_earnings#sthash.2Qgo2Li2.dpuf